Biodistribution of a 67Ga-labeled anti-TNF VHH single-domain antibody containing a bacterial albumin-binding domain (Zag)

Nuclear Medicine and Biology

Volumn 41, Issue S, 2014, Pages

  Morais, Maurício ^a   Cantante, Cátia ^b,c   Gano, Lurdes ^a   Santos, Isabel ^a   Lourenço, Sara ^d   Santos, Catarina ^b,c   Fontes, Carlos ^e   Aires da Silva, Frederico ^d   Gonçalves, João ^b,c   Correia, João D G ^a  

^a UNIVERSITY OF LISBON   (Portugal)

^b RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^c INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES   (Portugal)

^d TechnoPhage SA   (Portugal)

^e FACULDADE DE MEDICINA VETERINÁRIA   (Portugal)

Author keywords

Albumin binding domain; Biodistribution; Gallium 67; Plasma half life; Single domain antibodies

Indexed keywords

(4 ISOTHIOCYANATOBENZYL) 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID TUMOR NECROSIS FACTOR ANTIBODY SINGLE VARIABLE DOMAIN HEAVY CHAIN REGION ANTIBODY CONJUGATE; (4 ISOTHIOCYANATOBENZYL) 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID TUMOR NECROSIS FACTOR ANTIBODY SINGLE VARIABLE DOMAIN HEAVY CHAIN REGION ANTIBODY ZAG PROTEIN CONJUGATE; ALBUMIN; BACTERIAL PROTEIN; GALLIUM 67; HYBRID PROTEIN; NANOBODY; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; GALLIUM; IMMUNOGLOBULIN HEAVY CHAIN; TUMOR NECROSIS FACTOR ALPHA; ZAG PROTEIN, STREPTOCOCCAL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONJUGATION; CONTROLLED STUDY; FEMALE; IMMUNOREACTIVITY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PLASMA CLEARANCE; PLASMA HALF LIFE; PROTEIN BINDING; PROTEIN DOMAIN; STREPTOCOCCUS EQUI ZOOEPIDEMICUS; TISSUE DISTRIBUTION; ANIMAL; GENETICS; IMMUNOLOGY;

ANIMALS; BACTERIAL PROTEINS; FEMALE; GALLIUM RADIOISOTOPES; IMMUNOGLOBULIN HEAVY CHAINS; MICE; RECOMBINANT FUSION PROTEINS; SINGLE-DOMAIN ANTIBODIES; TISSUE DISTRIBUTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899084462     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2014.01.009     Document Type: Article

References (20)

1. Aires da Silva F., Corte-Real S., Goncalves J. Recombinant antibodies as therapeutic agents: pathways for modeling new biodrugs. BioDrugs 2008, 22:301-314.
2. Romer T., Leonhardt H., Rothbauer U. Engineering antibodies and proteins for molecular in vivo imaging. Curr Opin Biotechnol 2011, 22:882-887.
3. Goldsmith S.J., Signore A. An overview of the diagnostic and therapeutic use of monoclonal antibodies in medicine. Q J Nucl Med Mol Imaging 2010, 54:574-581.
4. Sharkey R.M., Goldenberg D.M. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 2005, 46(Suppl 1):115S-127S.
5. Vaneycken I., D'Huyvetter M., Hernot S., De Vos J., Xavier C., Devoogdt N., et al. Immuno-imaging using nanobodies. Curr Opin Biotechnol 2011, 22:877-881.
6. Batra S.K., Jain M., Wittel U.A., Chauhan S.C., Colcher D. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol 2002, 13:603-608.
7. Kontermann R.E. Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs 2009, 23:93-109.
8. Kontermann R.E. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 2011, 22:868-876.
9. Trussel S., Dumelin C., Frey K., Villa A., Buller F., Neri D. New Strategy for the Extension of the Serum Half-Life of Antibody Fragments. Bioconjug Chem 2009, 20:2286-2292.
10. Muller C., Struthers H., Winiger C., Zhernosekov K., Schibli R. DOTA Conjugate with an Albumin-Binding Entity Enables the First Folic Acid-Targeted Lu-177-Radionuclide Tumor Therapy in Mice. J Nucl Med 2013, 54:124-131.
11. Fanali G., di Masi A., Trezza V., Marino M., Fasano M., Ascenzi P. Human serum albumin: From bench to bedside. Mol Aspects Med 2012, 33:209-290.
12. Orlova A., Jonsson A., Rosik D., Lundqvist H., Lindborg M., Abrahmsen L., et al. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein. J Nucl Med 2013, 54:961-968.
13. Tolmachev V., Orlova A., Pehrson R., Galli J., Baastrup B., Andersson K., et al. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res 2007, 67:2773-2782.
14. Cantante C., Lourenço S., Morais M., Gano L., Santos C., Fontes C., et al. Albumin-binding domain (Zag) from Streptococcus zooepidemicus increases half-life affect blood clearance of anti-TNF VHH. 8th Annual PEGS conference. Boston 2012.
15. Cantante C., Lourenço S., Leandro J., Morais M., Gano L., Fontes C., et al. Albumin-binding domain from Streptococcus pyogenes protein H increases half-life and affect blood clearance of anti-TNF VHH 2012, PEGS Europe, Vienna, Austria.
16. Jonsson H., Lindmark H., Guss B. A Protein G-Related Cell-Surface Protein in Streptococcus-Zooepidemicus. Infect Immun 1995, 63:2968-2975.
17. Scasnar V., Vanlier J.E. The Use of Sep-Pak Si Cartridges for the Preparation of Gallium Chloride from the Citrate Solution. Eur J Nucl Med 1993, 20:273.
18. Silence K. USA; 2007/007249 A1.
19. Xavier C., Vaneycken I., D'huyvetter M., Heemskerk J., Keyaerts M., Vincke C., et al. Synthesis, Preclinical Validation, Dosimetry, and Toxicity of Ga-68-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer. J Nucl Med 2013, 54:776-784.
20. Stork R., Campigna E., Robert B., Muller D., Kontermann R.E. Biodistribution of a Bispecific Single-chain Diabody and Its Half-life Extended Derivatives. J Biol Chem 2009, 284:25612-25619.